Oral Biologics Market: Current Analysis and Forecast (2022-2028)

Oral Biologics Market: Current Analysis and Forecast (2022-2028)

Molecules originating from living cells, including those of microorganisms, plants, or animals, and utilized for the treatment, diagnosis, or prevention of various diseases are known as biologics drugs. Oral biologics products such as etanercept (Enbrel), adalimumab (Humira), and abatacept (Orencia), refer to biological drugs taken from oral disease indications. These drugs are widely used in the treatment of various diseases such as plaque psoriasis, ulcerative colitis, diabetes, Crohn’s disease, etc. Moreover, the growth of the oral biologics market can be attributed to the rising incidences of autoimmune diseases such as ankylosing spondylitis, rheumatoid arthritis, and others. For instance, according to the estimates of the Arthritis Foundation (AF), the global prevalence of rheumatoid arthritis is 0.5⁠ to 1% in developed countries.

The oral biologics market is expected to grow at a steady rate of around 22%. This is mainly due to the cost-effectiveness of biosimilars, loss of protection events of original drug manufacturers, strong product pipeline, company collaborations for research and development of new drugs, and increasing FDA approvals in major countries are some of the factors contributing to the growth of the market. For instance, in 2021, Amgen Inc., a biopharmaceutical company & Entera Bio Ltd. Entered into a research collaboration and license agreement to develop oral administration formulas of biologic drugs.

• Based on drug class, the market is segmented into glucagon-like peptide 1 (GLP-1) receptor agonist, recombinant enzyme, somatostatin analogue, guanylate cyclase-c agonist, hormone, and others. Among them, the glucagon-like peptide 1 (GLP-1) receptor agonist category is expected to hold the major market share during the forecast period. This is mainly due to the rising product approvals, product launches, partnerships, collaborations, mergers & acquisitions by key players, and r&d activities are expected to drive the market growth over the forecast period. For instance, in December 2020, Entera Bio Ltd. announced that the U.S. Food Drug and Administration had revived the company’s Investigational New Drug (IND) application for EB613, orally delivered human parathyroid hormone (1-34) or PTH, for the treatment of osteoporosis patients.
• On the basis of disease indication, the market is categorized into diabetes, hyperoxaluria, acromegaly, irritable bowel syndrome (IBS), chronic idiopathic constipation (CIC), and others. Among these, the diabetes category held a significant share of the market in 2021. This is mainly due to the increasing prevalence of type 1 diabetes globally and the rising prevalence of obesity will drive the segmental growth during the forecast period. For instance, as per the International Diabetes Federation (IDF), around 1.2 million youngsters and youths have type 1 diabetes in 2021.
• Based on distribution channel, the oral biologics market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies category is to witness higher adoption of oral biologics during the forecast period. This is mainly due to the availability of drugs for various diseases, cost-effectiveness, easy accessibility, and rising investment in the healthcare sector of the U.S. coupled with the increasing number of retail pharmacies & pharmaceutical outlets in developing and developed countries.
• For a better understanding of the market adoption of the oral biologics industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to held a dominant share in the market. The major factors such as well-established healthcare infrastructure, and rising incidences of chronic diseases such as cancer, autoimmune diseases, diabetes, arthritis, Alzheimer’s disease, and chronic kidney disease will contribute to the growth of the market. For instance, according to GLOBOCAN 2020, the number of new cancer cases diagnosed was 2,281,658 in the U.S. in 2020. Furthermore, rising investment in research and development activities by the key industry players and an increasing pipeline of products & new product launches in the market are also driving the market growth.
• Some of the major players operating in the market include Novo Nordisk A/S; Biocon; Oramed; Rani Therapeutics; EnteraBio Ltd.; AbbVie Inc.; Enteris BioPharma Inc.; Chiasma, Inc.; Allena Pharmaceuticals; Lilly.